MNMaria N. Navarro

Maria N. Navarro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria N. Navarro has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis

    by Aurea Oliva, Ignacio Cayuela, Jorge S Yebra, Yara Cuesta, Michael N Sack, Maria N Navarro, Javier Traba

    Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, in which IL–17–producing T cells play a central role. Nicotinamide riboside (NR), a precursor of NAD+, has recently emerged as a potential immunomodulatory intervention. Previous studies have shown that NR preferentially suppresses Th17 responsiveness in CD4+ T cells from individuals with psoriasis, but whether NR can attenuate psoriasiform inflammation in vivo remains poorly defined. Here, we investigated the effects of NR supplementation in a mouse model of imiquimod (IMQ)–induced psoriasiform skin inflammation. NR treatment markedly attenuated IMQ–induced splenomegaly and reduced epidermal thickening, indicating an improvement of both systemic and cutaneous inflammatory manifestations. Flow cytometric analysis of skin infiltrates revealed a reduction in inflammatory myeloid populations, including neutrophils and inflammatory monocyte–macrophages, together with a pronounced decrease in dermal TCR γδ and CD4+ T cells. Consistent with these findings, CD4+ T cells isolated from IMQ-treated mice displayed increased IL–17A production following ex vivo TCR stimulation, which was significantly reduced by NR supplementation in a dose-dependent manner. IFNγ and IL–4 responses were not significantly altered by NR in this setting. Furthermore, NR suppressed IL–17A production in Th17–polarized CD4+ T cells, while leaving Th1 and Th2 responses largely unaffected. Together, these findings show that NR treatment attenuates IMQ-induced psoriasiform skin inflammation in vivo and preferentially modulates IL–17A–associated CD4⁺ T–cell responses. The accompanying reduction in dermal γδ T–cell numbers suggests that NR may also influence innate-like T–cell populations involved in cutaneous inflammation, providing experimental evidence for NAD+ boosting as a potential immunomodulatory strategy in psoriasis.

  • Open Access

    Drug screening identifies Src/Abl inhibitor dasatinib as suppressor of IL-23 signaling in skin inflammation

    by Maria Jesus Valle-Pastor, Ignacio Cayuela, Jorge S. Yebra, Lis Senach-Rasilla, Gloria Pastor-Fernández, Aurea Oliva, Javier Traba, Maria N. Navarro

  • Open Access

    Mutation of the Polyproline Sequence in CD3ε Evidences TCR Signaling Requirements for Differentiation and Function of Pro-Inflammatory Tγδ17 Cells

    by Aldo Borroto, Balbino Alarcón, María N. Navarro

    Tγδ17 cells have emerged as a key population in the development of inflammatory and autoimmune conditions such as psoriasis. Thus, the therapeutic intervention of Tγδ17 cells can exert protective effects in this type of pathologies. Tγδ cells commit to IL-17 production during thymus development, and upon immune challenge, additional extrathymic signals induce the differentiation of uncommitted Tγδ cells into Tγδ17 effector cells. Despite the interest in Tγδ17 cells during the past 20 years, the role of TCR signaling in the generation and function of Tγδ17 cells has not been completely elucidated. While some studies point to the notion that Tγδ17 differentiation requires weak or no TCR signaling, other works suggest that Tγδ17 require the participation of specific kinases and adaptor molecules downstream of the TCR. Here we have examined the differentiation and pathogenic function of Tγδ17 cells in “knockin” mice bearing conservative mutations in the CD3ε polyproline rich sequence (KI-PRS) with attenuated TCR signaling due to lack of binding of the essential adaptor Nck. KI-PRS mice presented decreased frequency and numbers of Tγδ17 cells in adult thymus and lymph nodes. In the Imiquimod model of skin inflammation, KI-PRS presented attenuated skin inflammation parameters compared to wild-type littermates. Moreover, the generation, expansion and effector function Tγδ17 cells were impaired in KI-PRS mice upon Imiquimod challenge. Thus, we conclude that an intact CD3ε-PRS sequence is required for optimal differentiation and pathogenic function of Tγδ17 cells. These data open new opportunities for therapeutic targeting of specific TCR downstream effectors for treatment of Tγδ17-mediated diseases.


  • Open Access

    Galectin-1 Expression in CD8+ T Lymphocytes Controls Inflammation in Contact Hypersensitivity

    by Raquel Castillo-González, Danay Cibrian, Nieves Fernández-Gallego, Marta Ramírez-Huesca, María Laura Saiz, María N. Navarro, Manuel Fresno, Hortensia de la Fuente, Francisco Sánchez-Madrid


  • Open Access

    Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing

    by Maria N. Navarro, Manuel M. Gómez de Las Heras, Maria Mittelbrunn

    Metabolism is dynamically regulated to accompany immune cell function, and altered immunometabolism can result in impaired immune responses. Concomitantly, the pharmacological manipulation of metabolic processes offers an opportunity for therapeutic intervention in inflammatory disorders. The nicotinamide adenine dinucleotide (NAD+) is a critical metabolic intermediate that serves as enzyme cofactor in redox reactions, and is also used as a co‐substrate by many enzymes such as sirtuins, adenosine diphosphate ribose transferases and synthases. Through these activities, NAD+ metabolism regulates a broad spectrum of cellular functions such as energy metabolism, DNA repair, regulation of the epigenetic landscape and inflammation. Thus, the manipulation of NAD+ availability using pharmacological compounds such as NAD+ precursors can have immune‐modulatory properties in inflammation. Here, we discuss how the NAD+ metabolism contributes to the immune response and inflammatory conditions, with a special focus on multiple sclerosis, inflammatory bowel diseases and inflammageing.LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc


  • Open Access

    Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities

    by Gloria Pastor-Fernández, Isabel R. Mariblanca, María N. Navarro

    The interleukin 23 (IL-23) is a key pro-inflammatory cytokine in the development of chronic inflammatory diseases, such as psoriasis, inflammatory bowel diseases, multiple sclerosis, or rheumatoid arthritis. The pathological consequences of excessive IL-23 signaling have been linked to its ability to promote the production of inflammatory mediators, such as IL-17, IL-22, granulocyte-macrophage colony-stimulating (GM-CSF), or the tumor necrosis factor (TNFα) by target populations, mainly Th17 and IL-17-secreting TCRγδ cells (Tγδ17). Due to their pivotal role in inflammatory diseases, IL-23 and its downstream effector molecules have emerged as attractive therapeutic targets, leading to the development of neutralizing antibodies against IL-23 and IL-17 that have shown efficacy in different inflammatory diseases. Despite the success of monoclonal antibodies, there are patients that show no response or partial response to these treatments. Thus, effective therapies for inflammatory diseases may require the combination of multiple immune-modulatory drugs to prevent disease progression and to improve quality of life. Alternative strategies aimed at inhibiting intracellular signaling cascades using small molecule inhibitors or interfering peptides have not been fully exploited in the context of IL-23-mediated diseases. In this review, we discuss the current knowledge about proximal signaling events triggered by IL-23 upon binding to its membrane receptor to bring to the spotlight new opportunities for therapeutic intervention in IL-23-mediated pathologies.


  • Top Cited Papers

    T cells with dysfunctional mitochondria induce multimorbidity and premature senescence

    by Gabriela Desdín-Micó, Gonzalo Soto-Heredero, Juan Francisco Aranda, Jorge Oller, Elisa Carrasco, Enrique Gabandé-Rodríguez, Eva Maria Blanco, Arantzazu Alfranca, Lorena Cussó, Manuel Desco, et al.

    Inflammaging? Blame T cells!: Mitochondrial dysfunction in various tissues is a prominent characteristic of age-related deterioration, but it is unclear how mitochondrial dysfunction in particular cell types contributes to this process. Desdín-Micó et al. generated mice with T cells that were specifically deficient in a mitochondrial DNA–stabilizing protein. These animals exhibited multiple features associated with aging, including neurological, metabolic, muscular, and cardiovascular impairments. The defective T cells initiated an inflammatory program similar to that observed in older animals, a process called “inflammaging.” Blocking the cytokine tumor necrosis factor–α or administering precursors of the cofactor nicotinamide adenine dinucleotide restored many of these symptoms of senescence. These findings may potentially inform future therapies for age-associated diseases, as well as cachexia and cytokine-release syndrome. Science , this issue p. 1371


  • Open Access

    IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics

    by Candelas Álvarez-Salamero, Raquel Castillo-González, Gloria Pastor-Fernández, Isabel R. Mariblanca, Jesús Pino, Danay Cibrian, María N. Navarro

    Interleukin 23 (IL-23) triggers pathogenic features in pro-inflammatory, IL-17-secreting T cells (Th17 and Tγδ17) that play a key role in the development of inflammatory diseases. However, the IL-23 signaling cascade remains largely undefined. Here, we used quantitative phosphoproteomics to characterize IL-23 signaling in primary murine Th17 cells. We quantified 6,888 phosphorylation sites in Th17 cells and found 168 phosphorylations regulated upon IL-23 stimulation. IL-23 increased the phosphorylation of the myosin regulatory light chain (RLC), an actomyosin contractibility marker, in Th17 and Tγδ17 cells. IL-23-induced RLC phosphorylation required Janus kinase 2 (JAK2) and Rho-associated protein kinase (ROCK) catalytic activity, and further study of the IL-23/ROCK connection revealed an unexpected role of IL-23 in the migration of Tγδ17 and Th17 cells through ROCK activation. In addition, pharmacological inhibition of ROCK reduced Tγδ17 recruitment to inflamed skin upon challenge with inflammatory agent Imiquimod. This work (i) provides new insights into phosphorylation networks that control Th17 cells, (ii) widely expands the current knowledge on IL-23 signaling, and (iii) contributes to the increasing list of immune cells subsets characterized by global phosphoproteomic approaches.


  • Open Access

    Lighting Up T Lymphocyte Signaling with Quantitative Phosphoproteomics

    by Candelas Álvarez-Salamero, Raquel Castillo-González, María N. Navarro

    Phosphorylation is the most abundant post-translational modification, regulating several aspects of protein and cell function. Quantitative phosphoproteomics approaches have expanded the scope of phosphorylation analysis enabling the quantification of changes in thousands of phosphorylation sites simultaneously in two or more conditions. These approaches offer a global view of the impact of cellular perturbations such as extracellular stimuli or gene ablation in intracellular signaling networks. Such great potential also brings on a new challenge: to identify, among the thousands of phosphorylations found in global phosphoproteomics studies, the small subset of site-specific phosphorylations expected to be functionally relevant. This review focus on updating and integrating findings on T lymphocyte signaling generated using global phosphoproteomics approaches, drawing attention on the biological relevance of the obtained data.


  • Open Access

    Glucose represses dendritic cell-induced T cell responses

    by Simon J. Lawless, Nidhi Kedia-Mehta, Jessica F. Walls, Ryan McGarrigle, Orla Convery, Linda V. Sinclair, Maria N. Navarro, James Murray, David K. Finlay

    Glucose and glycolysis are important for the proinflammatory functions of many immune cells, and depletion of glucose in pathological microenvironments is associated with defective immune responses. Here we show a contrasting function for glucose in dendritic cells (DCs), as glucose represses the proinflammatory output of LPS-stimulated DCs and inhibits DC-induced T-cell responses. A glucose-sensitive signal transduction circuit involving the mTOR complex 1 (mTORC1), HIF1α and inducible nitric oxide synthase (iNOS) coordinates DC metabolism and function to limit DC-stimulated T-cell responses. When multiple T cells interact with a DC, they compete for nutrients, which can limit glucose availability to the DCs. In such DCs, glucose-dependent signalling is inhibited, altering DC outputs and enhancing T-cell responses. These data reveal a mechanism by which T cells regulate the DC microenvironment to control DC-induced T-cell responses and indicate that glucose is an important signal for shaping immune responses.